These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17611218)

  • 1. Cardiotoxicity of trastuzumab in clinical practice.
    McArthur HL; Chia S
    N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
    [No Abstract]   [Full Text] [Related]  

  • 2. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
    Goel S; Beith JM
    J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 4. Trastuzumab-induced cardiac dysfunction.
    Panjrath GS; Jain D
    Nucl Med Commun; 2007 Feb; 28(2):69-73. PubMed ID: 17198344
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
    Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab cardiac side effects: only time will tell.
    Levine MN
    J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
    Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
    Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab trials steal show at ASCO meeting.
    Tuma RS
    J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab for early breast cancer.
    Thorat M
    Lancet; 2006 Jan; 367(9505):108. PubMed ID: 16413867
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the introduction of new drugs--Herceptin to cardiotoxicity.
    Routledge HC; Rea DW; Steeds RP
    Clin Med (Lond); 2006; 6(5):478-81. PubMed ID: 17080896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of myocardial dysfunction during cancer chemotherapy with tissue Doppler imaging: a canary in the coal mine?
    Hoit BD
    J Am Soc Echocardiogr; 2009 Apr; 22(4):425-6. PubMed ID: 19345310
    [No Abstract]   [Full Text] [Related]  

  • 14. Irreversible cardiotoxicity after adjuvant treatment with trastuzumab in a case of breast cancer.
    Bordin P; Volpe C; Adami G; Moretti V; Ermacora P
    Tumori; 2008; 94(5):777-8. PubMed ID: 19112961
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.
    Murray LJ; Ramakrishnan S; O'Toole L; Manifold IH; Purohit OP; Coleman RE
    Breast; 2010 Oct; 19(5):339-44. PubMed ID: 20226661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab.
    Martins SJ; Modesto Dos Santos V; Thommen Teles L; Alves Leite V
    Rev Med Chil; 2012 Jun; 140(6):763-6. PubMed ID: 23282614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of trastuzumab-related cardiac dysfunction.
    Carver JR
    Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.